The Src family kinases Hck, Fgr, and Lyn are recruited by IL-6, typically increased in the MM microenvironment, and for this reason they have been proposed as a novel target to augment the activity of current MM therapies [36,37]. This evidence concerns the gene IL6 and Miyoshi myopathy.